Pharma deal potentially great news, but there are worries over funding
Daniel Elkeles responds to the UK-US pharmaceuticals deal.
Responding to the announcement of the UK-US pharmaceuticals deal, the chief executive of NHS Providers, Daniel Elkeles, said:
"This deal is potentially very good news for patients, for the NHS and for UK life sciences.
"It is great that NHS patients will have increased access to groundbreaking new treatments.
"The announcement also builds on the longstanding close partnership between the NHS and the pharmaceutical industry, making this the best place in the world to carry out clinical trials.
"However it is not yet clear how it will be paid for.
"There is absolutely no slack in current published NHS spending plans for this major commitment and that is a real worry for trust leaders."
Related articles
- Training
NHS finance for senior leaders
3 March 20279:30 - 16:00Online
Develop a greater understanding of NHS financial principles, funding flows and reporting to strengthen your confidence to effectively contribute at board level.
Leadership
Finance
- Conference
WelshConfed26: Iechyd a gofal yng Nghymru: os nad nawr, pryd?
3 - 4 November 2026In-person
Mae Cynhadledd ac arddangosfa Flynyddol Conffederasiwn GIG Cymru yn uno arweinwyr yn nigwyddiad iechyd a gofal Cymru eleni.
Community
Cross-sector partnerships
Digital
Improvement
Leadership
Prevention
Primary care
Workforce
- Conference
WelshConfed26: Welsh NHS Confederation Annual Conference & Exhibition
3 - 4 November 2026In-person
WelshConfed26 unites leaders at Wales' health and care event of the year.
Community
Cross-sector partnerships
Digital
Improvement
Leadership
Prevention
Primary care
Workforce